Literature DB >> 30600480

Immunological cure of HBV infection.

Julia Lang1, Christoph Neumann-Haefelin1, Robert Thimme2.   

Abstract

Chronic hepatitis B virus (HBV) infection is a major global health burden and cure is rarely achieved by current antiviral therapies. Therefore, there is an urgent need for new therapeutic options. Immune modulation with the goal to restore dysfunctional HBV-specific immunity is an interesting target for new therapeutic strategies. Based on the current evidence on immunology in resolving and persistent HBV infection, we will review the growing field of immunotherapeutic approaches for treatment of chronic HBV infection. We will also discuss the challenge of a heterogeneous patient population and personalized treatment as a possible key factor of success.

Entities:  

Keywords:  Adaptive immunity; CD4+ T-lymphocytes; CD8+ T-lymphocytes; Hepatitis B; Immunotherapy

Mesh:

Substances:

Year:  2019        PMID: 30600480     DOI: 10.1007/s12072-018-9912-8

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  17 in total

Review 1.  Novel therapeutic strategies for chronic hepatitis B.

Authors:  Sandra Phillips; Ravi Jagatia; Shilpa Chokshi
Journal:  Virulence       Date:  2022-12       Impact factor: 5.428

2.  Targeting Viral cccDNA for Cure of Chronic Hepatitis B.

Authors:  Gaëtan Ligat; Kaku Goto; Eloi Verrier; Thomas F Baumert
Journal:  Curr Hepatol Rep       Date:  2020-07-10

Review 3.  Animal Models of Hepatitis B Virus Infection-Success, Challenges, and Future Directions.

Authors:  Yongzhen Liu; Stephanie Maya; Alexander Ploss
Journal:  Viruses       Date:  2021-04-28       Impact factor: 5.048

Review 4.  Host Genetic Determinants of Hepatitis B Virus Infection.

Authors:  Zhenhua Zhang; Changtai Wang; Zhongping Liu; Guizhou Zou; Jun Li; Mengji Lu
Journal:  Front Genet       Date:  2019-08-13       Impact factor: 4.599

5.  Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: a longitudinal cohort study.

Authors:  Min Zhang; Guangdi Li; Jia Shang; Chen Pan; Minxiang Zhang; Zhibiao Yin; Qing Xie; Yanzhong Peng; Qing Mao; Xinqiang Xiao; Yongfang Jiang; Kaizhong Luo; Yun Xu; Hai Ding; Wenzhou Fan; Vidaurre Diego; Mahmoud Reza Pourkarim; Erik De Clercq; Guiqiang Wang; Guozhong Gong
Journal:  Hepatol Int       Date:  2020-02-25       Impact factor: 6.047

Review 6.  Beyond HIV infection: Neglected and varied impacts of CCR5 and CCR5Δ32 on viral diseases.

Authors:  Joel Henrique Ellwanger; Bruna Kulmann-Leal; Valéria de Lima Kaminski; Andressa Gonçalves Rodrigues; Marcelo Alves de Souza Bragatte; José Artur Bogo Chies
Journal:  Virus Res       Date:  2020-05-30       Impact factor: 3.303

Review 7.  Hepatitis B virus-host interactions and novel targets for viral cure.

Authors:  Gaëtan Ligat; Eloi R Verrier; Michael Nassal; Thomas F Baumert
Journal:  Curr Opin Virol       Date:  2021-05-22       Impact factor: 7.121

Review 8.  CD4+ T Cells in Chronic Hepatitis B and T Cell-Directed Immunotherapy.

Authors:  Sonja I Buschow; Diahann T S L Jansen
Journal:  Cells       Date:  2021-05-06       Impact factor: 6.600

9.  A bioinformatics investigation into molecular mechanism of Yinzhihuang granules for treating hepatitis B by network pharmacology and molecular docking verification.

Authors:  Jingyuan Zhang; Xinkui Liu; Wei Zhou; Guoliang Cheng; Jiarui Wu; Siyu Guo; Shanshan Jia; Yingying Liu; Bingbing Li; Xiaomeng Zhang; Miaomiao Wang
Journal:  Sci Rep       Date:  2020-07-10       Impact factor: 4.379

10.  Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial.

Authors:  Fabien Zoulim; Claire Fournier; François Habersetzer; Martin Sprinzl; Stanislas Pol; Carla S Coffin; Vincent Leroy; Mang Ma; Heiner Wedemeyer; Ansgar W Lohse; Robert Thimme; Karine Lugardon; Perrine Martin; Bérangère Bastien; Benoit Sansas; Nathalie Adda; Celine Halluard; Kaïdre Bendjama; Maud Brandely; Geneviève Inchauspé
Journal:  Hum Vaccin Immunother       Date:  2019-10-04       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.